KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis Article Swipe
Rebecca Goulding
,
Matthew Chenoweth
,
Gebra Cuyún Carter
,
Mark E. Boye
,
Kristin M. Sheffield
,
William J. John
,
Mark S. Leusch
,
Catherine E. Muehlenbein
,
Li Li
,
Min‐Hua Jen
,
Adina Rojubally
,
Jeroen J. Jansen
,
Eric Druyts
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1016/j.ctarc.2020.100200
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.1016/j.ctarc.2020.100200
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.ctarc.2020.100200
- OA Status
- gold
- Cited By
- 59
- References
- 69
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3045278119
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3045278119Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.ctarc.2020.100200Digital Object Identifier
- Title
-
KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysisWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-01-01Full publication date if available
- Authors
-
Rebecca Goulding, Matthew Chenoweth, Gebra Cuyún Carter, Mark E. Boye, Kristin M. Sheffield, William J. John, Mark S. Leusch, Catherine E. Muehlenbein, Li Li, Min‐Hua Jen, Adina Rojubally, Jeroen J. Jansen, Eric DruytsList of authors in order
- Landing page
-
https://doi.org/10.1016/j.ctarc.2020.100200Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.ctarc.2020.100200Direct OA link when available
- Concepts
-
KRAS, Medicine, Internal medicine, Oncology, Meta-analysis, Hazard ratio, Observational study, Lung cancer, Randomized controlled trial, Systematic review, Cancer, MEDLINE, Confidence interval, Colorectal cancer, Biology, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
59Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 8, 2024: 20, 2023: 14, 2022: 10, 2021: 6Per-year citation counts (last 5 years)
- References (count)
-
69Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3045278119 |
|---|---|
| doi | https://doi.org/10.1016/j.ctarc.2020.100200 |
| ids.doi | https://doi.org/10.1016/j.ctarc.2020.100200 |
| ids.mag | 3045278119 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/32750661 |
| ids.openalex | https://openalex.org/W3045278119 |
| fwci | 4.79231994 |
| mesh[0].qualifier_ui | Q000494 |
| mesh[0].descriptor_ui | D000971 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | pharmacology |
| mesh[0].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D000971 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[2].qualifier_ui | Q000037 |
| mesh[2].descriptor_ui | D014408 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | antagonists & inhibitors |
| mesh[2].descriptor_name | Biomarkers, Tumor |
| mesh[3].qualifier_ui | Q000235 |
| mesh[3].descriptor_ui | D014408 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | genetics |
| mesh[3].descriptor_name | Biomarkers, Tumor |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D002289 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[5].qualifier_ui | Q000235 |
| mesh[5].descriptor_ui | D002289 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | genetics |
| mesh[5].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[6].qualifier_ui | Q000401 |
| mesh[6].descriptor_ui | D002289 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | mortality |
| mesh[6].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[7].qualifier_ui | Q000556 |
| mesh[7].descriptor_ui | D002289 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | secondary |
| mesh[7].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D004252 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | DNA Mutational Analysis |
| mesh[9].qualifier_ui | Q000037 |
| mesh[9].descriptor_ui | D066246 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | antagonists & inhibitors |
| mesh[9].descriptor_name | ErbB Receptors |
| mesh[10].qualifier_ui | Q000235 |
| mesh[10].descriptor_ui | D066246 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | genetics |
| mesh[10].descriptor_name | ErbB Receptors |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D006801 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Humans |
| mesh[12].qualifier_ui | Q000188 |
| mesh[12].descriptor_ui | D008175 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | drug therapy |
| mesh[12].descriptor_name | Lung Neoplasms |
| mesh[13].qualifier_ui | Q000235 |
| mesh[13].descriptor_ui | D008175 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | genetics |
| mesh[13].descriptor_name | Lung Neoplasms |
| mesh[14].qualifier_ui | Q000401 |
| mesh[14].descriptor_ui | D008175 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | mortality |
| mesh[14].descriptor_name | Lung Neoplasms |
| mesh[15].qualifier_ui | Q000473 |
| mesh[15].descriptor_ui | D008175 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | pathology |
| mesh[15].descriptor_name | Lung Neoplasms |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D009154 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Mutation |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D009367 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Neoplasm Staging |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D064887 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Observational Studies as Topic |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D011379 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Prognosis |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D000077982 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Progression-Free Survival |
| mesh[21].qualifier_ui | Q000494 |
| mesh[21].descriptor_ui | D047428 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | pharmacology |
| mesh[21].descriptor_name | Protein Kinase Inhibitors |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D047428 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Protein Kinase Inhibitors |
| mesh[23].qualifier_ui | Q000235 |
| mesh[23].descriptor_ui | D016283 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | genetics |
| mesh[23].descriptor_name | Proto-Oncogene Proteins p21(ras) |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D016032 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Randomized Controlled Trials as Topic |
| mesh[25].qualifier_ui | Q000494 |
| mesh[25].descriptor_ui | D000971 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | pharmacology |
| mesh[25].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[26].qualifier_ui | Q000627 |
| mesh[26].descriptor_ui | D000971 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | therapeutic use |
| mesh[26].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[27].qualifier_ui | Q000037 |
| mesh[27].descriptor_ui | D014408 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | antagonists & inhibitors |
| mesh[27].descriptor_name | Biomarkers, Tumor |
| mesh[28].qualifier_ui | Q000235 |
| mesh[28].descriptor_ui | D014408 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | genetics |
| mesh[28].descriptor_name | Biomarkers, Tumor |
| mesh[29].qualifier_ui | Q000188 |
| mesh[29].descriptor_ui | D002289 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | drug therapy |
| mesh[29].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[30].qualifier_ui | Q000235 |
| mesh[30].descriptor_ui | D002289 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | genetics |
| mesh[30].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[31].qualifier_ui | Q000401 |
| mesh[31].descriptor_ui | D002289 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | mortality |
| mesh[31].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[32].qualifier_ui | Q000556 |
| mesh[32].descriptor_ui | D002289 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | secondary |
| mesh[32].descriptor_name | Carcinoma, Non-Small-Cell Lung |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D004252 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | DNA Mutational Analysis |
| mesh[34].qualifier_ui | Q000037 |
| mesh[34].descriptor_ui | D066246 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | antagonists & inhibitors |
| mesh[34].descriptor_name | ErbB Receptors |
| mesh[35].qualifier_ui | Q000235 |
| mesh[35].descriptor_ui | D066246 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | genetics |
| mesh[35].descriptor_name | ErbB Receptors |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D006801 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Humans |
| mesh[37].qualifier_ui | Q000188 |
| mesh[37].descriptor_ui | D008175 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | drug therapy |
| mesh[37].descriptor_name | Lung Neoplasms |
| mesh[38].qualifier_ui | Q000235 |
| mesh[38].descriptor_ui | D008175 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | genetics |
| mesh[38].descriptor_name | Lung Neoplasms |
| mesh[39].qualifier_ui | Q000401 |
| mesh[39].descriptor_ui | D008175 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | mortality |
| mesh[39].descriptor_name | Lung Neoplasms |
| mesh[40].qualifier_ui | Q000473 |
| mesh[40].descriptor_ui | D008175 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | pathology |
| mesh[40].descriptor_name | Lung Neoplasms |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D009154 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | Mutation |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D009367 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Neoplasm Staging |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D064887 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Observational Studies as Topic |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D011379 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Prognosis |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D000077982 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Progression-Free Survival |
| mesh[46].qualifier_ui | Q000494 |
| mesh[46].descriptor_ui | D047428 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | pharmacology |
| mesh[46].descriptor_name | Protein Kinase Inhibitors |
| mesh[47].qualifier_ui | Q000627 |
| mesh[47].descriptor_ui | D047428 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | therapeutic use |
| mesh[47].descriptor_name | Protein Kinase Inhibitors |
| mesh[48].qualifier_ui | Q000235 |
| mesh[48].descriptor_ui | D016283 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | genetics |
| mesh[48].descriptor_name | Proto-Oncogene Proteins p21(ras) |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D016032 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Randomized Controlled Trials as Topic |
| type | review |
| title | KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis |
| biblio.issue | |
| biblio.volume | 24 |
| biblio.last_page | 100200 |
| biblio.first_page | 100200 |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T11067 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9944999814033508 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Colorectal Cancer Treatments and Studies |
| topics[2].id | https://openalex.org/T12505 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9912999868392944 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Peptidase Inhibition and Analysis |
| is_xpac | False |
| apc_list.value | 1650 |
| apc_list.currency | USD |
| apc_list.value_usd | 1650 |
| apc_paid.value | 1650 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1650 |
| concepts[0].id | https://openalex.org/C2781187634 |
| concepts[0].level | 4 |
| concepts[0].score | 0.8733326196670532 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q20969980 |
| concepts[0].display_name | KRAS |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.8133891224861145 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.7751933932304382 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C143998085 |
| concepts[3].level | 1 |
| concepts[3].score | 0.7375596761703491 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[3].display_name | Oncology |
| concepts[4].id | https://openalex.org/C95190672 |
| concepts[4].level | 2 |
| concepts[4].score | 0.669857919216156 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q815382 |
| concepts[4].display_name | Meta-analysis |
| concepts[5].id | https://openalex.org/C207103383 |
| concepts[5].level | 3 |
| concepts[5].score | 0.6326441764831543 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q3930246 |
| concepts[5].display_name | Hazard ratio |
| concepts[6].id | https://openalex.org/C23131810 |
| concepts[6].level | 2 |
| concepts[6].score | 0.5340278148651123 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q818574 |
| concepts[6].display_name | Observational study |
| concepts[7].id | https://openalex.org/C2776256026 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4665403664112091 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[7].display_name | Lung cancer |
| concepts[8].id | https://openalex.org/C168563851 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4645528495311737 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[8].display_name | Randomized controlled trial |
| concepts[9].id | https://openalex.org/C189708586 |
| concepts[9].level | 3 |
| concepts[9].score | 0.41225653886795044 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1504425 |
| concepts[9].display_name | Systematic review |
| concepts[10].id | https://openalex.org/C121608353 |
| concepts[10].level | 2 |
| concepts[10].score | 0.37923604249954224 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[10].display_name | Cancer |
| concepts[11].id | https://openalex.org/C2779473830 |
| concepts[11].level | 2 |
| concepts[11].score | 0.2619256377220154 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1540899 |
| concepts[11].display_name | MEDLINE |
| concepts[12].id | https://openalex.org/C44249647 |
| concepts[12].level | 2 |
| concepts[12].score | 0.14300689101219177 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[12].display_name | Confidence interval |
| concepts[13].id | https://openalex.org/C526805850 |
| concepts[13].level | 3 |
| concepts[13].score | 0.12602341175079346 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q188874 |
| concepts[13].display_name | Colorectal cancer |
| concepts[14].id | https://openalex.org/C86803240 |
| concepts[14].level | 0 |
| concepts[14].score | 0.07040002942085266 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[14].display_name | Biology |
| concepts[15].id | https://openalex.org/C55493867 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[15].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/kras |
| keywords[0].score | 0.8733326196670532 |
| keywords[0].display_name | KRAS |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.8133891224861145 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.7751933932304382 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/oncology |
| keywords[3].score | 0.7375596761703491 |
| keywords[3].display_name | Oncology |
| keywords[4].id | https://openalex.org/keywords/meta-analysis |
| keywords[4].score | 0.669857919216156 |
| keywords[4].display_name | Meta-analysis |
| keywords[5].id | https://openalex.org/keywords/hazard-ratio |
| keywords[5].score | 0.6326441764831543 |
| keywords[5].display_name | Hazard ratio |
| keywords[6].id | https://openalex.org/keywords/observational-study |
| keywords[6].score | 0.5340278148651123 |
| keywords[6].display_name | Observational study |
| keywords[7].id | https://openalex.org/keywords/lung-cancer |
| keywords[7].score | 0.4665403664112091 |
| keywords[7].display_name | Lung cancer |
| keywords[8].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[8].score | 0.4645528495311737 |
| keywords[8].display_name | Randomized controlled trial |
| keywords[9].id | https://openalex.org/keywords/systematic-review |
| keywords[9].score | 0.41225653886795044 |
| keywords[9].display_name | Systematic review |
| keywords[10].id | https://openalex.org/keywords/cancer |
| keywords[10].score | 0.37923604249954224 |
| keywords[10].display_name | Cancer |
| keywords[11].id | https://openalex.org/keywords/medline |
| keywords[11].score | 0.2619256377220154 |
| keywords[11].display_name | MEDLINE |
| keywords[12].id | https://openalex.org/keywords/confidence-interval |
| keywords[12].score | 0.14300689101219177 |
| keywords[12].display_name | Confidence interval |
| keywords[13].id | https://openalex.org/keywords/colorectal-cancer |
| keywords[13].score | 0.12602341175079346 |
| keywords[13].display_name | Colorectal cancer |
| keywords[14].id | https://openalex.org/keywords/biology |
| keywords[14].score | 0.07040002942085266 |
| keywords[14].display_name | Biology |
| language | en |
| locations[0].id | doi:10.1016/j.ctarc.2020.100200 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210186504 |
| locations[0].source.issn | 2468-2942 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2468-2942 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Cancer Treatment and Research Communications |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancer Treatment and Research Communications |
| locations[0].landing_page_url | https://doi.org/10.1016/j.ctarc.2020.100200 |
| locations[1].id | pmid:32750661 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancer treatment and research communications |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/32750661 |
| locations[2].id | pmh:oai:doaj.org/article:8d4a2489397e4e478a6287ecb9ffb2ec |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].source.host_organization_lineage | |
| locations[2].license | cc-by-sa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | https://openalex.org/licenses/cc-by-sa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Cancer Treatment and Research Communications, Vol 24, Iss , Pp 100200- (2020) |
| locations[2].landing_page_url | https://doaj.org/article/8d4a2489397e4e478a6287ecb9ffb2ec |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5010785803 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-0716-5126 |
| authorships[0].author.display_name | Rebecca Goulding |
| authorships[0].affiliations[0].raw_affiliation_string | Precision Xtract, United States |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Rebecca Ellen Goulding |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Precision Xtract, United States |
| authorships[1].author.id | https://openalex.org/A5086521808 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5614-9803 |
| authorships[1].author.display_name | Matthew Chenoweth |
| authorships[1].affiliations[0].raw_affiliation_string | Precision Xtract, United States |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Matthew Chenoweth |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Precision Xtract, United States |
| authorships[2].author.id | https://openalex.org/A5031548464 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6549-0069 |
| authorships[2].author.display_name | Gebra Cuyún Carter |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[2].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[2].institutions[0].id | https://openalex.org/I168537998 |
| authorships[2].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[2].institutions[0].type | company |
| authorships[2].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Eli Lilly (United States) |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Gebra Cuyun Carter |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[3].author.id | https://openalex.org/A5109941587 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Mark E. Boye |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[3].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[3].institutions[0].id | https://openalex.org/I168537998 |
| authorships[3].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[3].institutions[0].type | company |
| authorships[3].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Eli Lilly (United States) |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Mark Ernest Boye |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[4].author.id | https://openalex.org/A5043605449 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-3940-1795 |
| authorships[4].author.display_name | Kristin M. Sheffield |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[4].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[4].institutions[0].id | https://openalex.org/I168537998 |
| authorships[4].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Eli Lilly (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Kristin M Sheffield |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[5].author.id | https://openalex.org/A5109305896 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | William J. John |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[5].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[5].institutions[0].id | https://openalex.org/I168537998 |
| authorships[5].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Eli Lilly (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | William J John |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[6].author.id | https://openalex.org/A5086998139 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-4771-9525 |
| authorships[6].author.display_name | Mark S. Leusch |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[6].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[6].institutions[0].id | https://openalex.org/I168537998 |
| authorships[6].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Eli Lilly (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Mark Steven Leusch |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[7].author.id | https://openalex.org/A5073922485 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-6753-3571 |
| authorships[7].author.display_name | Catherine E. Muehlenbein |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[7].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[7].institutions[0].id | https://openalex.org/I168537998 |
| authorships[7].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Eli Lilly (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Catherine Elizabeth Muehlenbein |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[8].author.id | https://openalex.org/A5100361376 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-3380-9159 |
| authorships[8].author.display_name | Li Li |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[8].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[8].institutions[0].id | https://openalex.org/I168537998 |
| authorships[8].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[8].institutions[0].type | company |
| authorships[8].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Eli Lilly (United States) |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Li Li |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[9].author.id | https://openalex.org/A5071015984 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-4916-0107 |
| authorships[9].author.display_name | Min‐Hua Jen |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I168537998 |
| authorships[9].affiliations[0].raw_affiliation_string | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[9].institutions[0].id | https://openalex.org/I168537998 |
| authorships[9].institutions[0].ror | https://ror.org/01qat3289 |
| authorships[9].institutions[0].type | company |
| authorships[9].institutions[0].lineage | https://openalex.org/I168537998 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Eli Lilly (United States) |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Min-Hua Jen |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Eli Lilly and Company, Corporate Center, Indianapolis, IN 46285, United States |
| authorships[10].author.id | https://openalex.org/A5050969532 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Adina Rojubally |
| authorships[10].affiliations[0].raw_affiliation_string | Precision Xtract, United States |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Adina Rojubally |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Precision Xtract, United States |
| authorships[11].author.id | https://openalex.org/A5006037899 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4836-8990 |
| authorships[11].author.display_name | Jeroen J. Jansen |
| authorships[11].affiliations[0].raw_affiliation_string | Precision Xtract, United States |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Jeroen Jansen |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Precision Xtract, United States |
| authorships[12].author.id | https://openalex.org/A5103442059 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Eric Druyts |
| authorships[12].affiliations[0].raw_affiliation_string | Precision Xtract, United States |
| authorships[12].author_position | last |
| authorships[12].raw_author_name | Eric Druyts |
| authorships[12].is_corresponding | True |
| authorships[12].raw_affiliation_strings | Precision Xtract, United States |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.ctarc.2020.100200 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-12T23:11:45.498971 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W3030972949, https://openalex.org/W4283712951, https://openalex.org/W4229832877, https://openalex.org/W4306404900, https://openalex.org/W3111812619, https://openalex.org/W4248366929, https://openalex.org/W2590035663, https://openalex.org/W2914997899, https://openalex.org/W4229670017, https://openalex.org/W4294636802 |
| cited_by_count | 59 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 8 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 20 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 14 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 10 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 6 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 1 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1016/j.ctarc.2020.100200 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210186504 |
| best_oa_location.source.issn | 2468-2942 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2468-2942 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Cancer Treatment and Research Communications |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancer Treatment and Research Communications |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.ctarc.2020.100200 |
| primary_location.id | doi:10.1016/j.ctarc.2020.100200 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210186504 |
| primary_location.source.issn | 2468-2942 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2468-2942 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Cancer Treatment and Research Communications |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancer Treatment and Research Communications |
| primary_location.landing_page_url | https://doi.org/10.1016/j.ctarc.2020.100200 |
| publication_date | 2020-01-01 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2753051611, https://openalex.org/W2032263978, https://openalex.org/W6638456460, https://openalex.org/W1608661165, https://openalex.org/W2320138981, https://openalex.org/W2148174696, https://openalex.org/W2172010139, https://openalex.org/W2134370756, https://openalex.org/W2271051170, https://openalex.org/W1134514068, https://openalex.org/W2341157401, https://openalex.org/W1989595177, https://openalex.org/W1991874467, https://openalex.org/W2037475133, https://openalex.org/W2037791152, https://openalex.org/W2045509446, https://openalex.org/W2166923287, https://openalex.org/W2128059540, https://openalex.org/W1998280666, https://openalex.org/W2100741073, https://openalex.org/W1982967337, https://openalex.org/W2098923148, https://openalex.org/W2126930838, https://openalex.org/W2157823046, https://openalex.org/W2062311207, https://openalex.org/W1984004254, https://openalex.org/W2081957151, https://openalex.org/W1892652546, https://openalex.org/W2122327814, https://openalex.org/W1969525589, https://openalex.org/W2500954855, https://openalex.org/W2155338842, https://openalex.org/W2139720565, https://openalex.org/W2105026490, https://openalex.org/W2149654081, https://openalex.org/W2019539885, https://openalex.org/W2331413585, https://openalex.org/W2287891688, https://openalex.org/W2104347254, https://openalex.org/W2035390137, https://openalex.org/W2320121320, https://openalex.org/W2345691009, https://openalex.org/W2120420501, https://openalex.org/W2144187094, https://openalex.org/W2107879261, https://openalex.org/W2131795655, https://openalex.org/W1523764380, https://openalex.org/W2104748005, https://openalex.org/W2107304950, https://openalex.org/W2163885776, https://openalex.org/W1599750485, https://openalex.org/W1553102093, https://openalex.org/W2019527474, https://openalex.org/W2085739080, https://openalex.org/W2160725767, https://openalex.org/W2085433103, https://openalex.org/W2304373741, https://openalex.org/W2101581271, https://openalex.org/W2102743085, https://openalex.org/W2165651085, https://openalex.org/W2140126391, https://openalex.org/W2123172787, https://openalex.org/W2148783573, https://openalex.org/W2097026987, https://openalex.org/W1948677875, https://openalex.org/W2099556905, https://openalex.org/W2142850084, https://openalex.org/W2119002966, https://openalex.org/W1819015028 |
| referenced_works_count | 69 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 89 |
| corresponding_author_ids | https://openalex.org/A5103442059 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 13 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8100000023841858 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.95306515 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |